KNSA: מחיר למכירות Kiniksa Pharmaceuticals Ltd

The P/S business valuation on the GURU.Markets dynamic chart illustrates an ecosystem for treating rare cardiovascular pathologies, where the 5.00 value characterizes this level. Kiniksa Pharmaceuticals (KNSA) is developing therapies for immune failures through partnerships with biotech institutes. Strong patents in the inflammatory heart disease niche ensure high margins and a lack of direct market equivalents.
פילוחים אנליטיים של חברת kiniksa.com (KNSA)

The monopoly status of Kiniksa Pharmaceuticals (KNSA) in the treatment of inflammatory diseases, secured by antibody patents, directly impacts the market valuation of its revenue. The current value of 5.00 reflects the ratio of market capitalization to sales volume, demonstrating how much investors are willing to pay per unit of revenue; the history of the price-to-sales multiple allows for an assessment of the balance between the asset's prestige and the risks of overvaluation.